Brian Ross, Ph.D.

Roger A. Berg Professor, Radiology
Professor, Biological Chemistry

2071 BSRB
109 Zina Pitcher Place
Ann Arbor, MI 48109-2200

(734) 763-2099

Areas of Interest

Molecular imaging is as an exciting area of multidisciplinary research that allows physiology and molecular processes to be visualized in living tissue. Instrumentation involved in molecular imaging includes magnetic resonance imaging (MRI), bioluminescence imaging (BLI), positron emission tomography (PET) and x-ray computer assisted tomography (CT). As part of the Center for Molecular Imaging, we are developing applications for imaging to allow for investigations of cancer growth and response to therapy including noninvasive detection of molecular signaling events in living tissue. Translation of developed algorithms into the clinical setting is ongoing.

Honors & Awards

Editor-in-Chief, Tomography, 2015
Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine, 2014
Distinguished Investigator Award, Academy of Radiology Research, 2013
Roger A. Berg Professorship, University of Michigan, 2012
Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine, 2011
Elected Fellow, International Society for Magnetic Resonance in Medicine, 2009
Scientific Advisory Board, Cancer Research UK Cambridge Research Institute, 2007
Elected President, Society for Molecular Imaging, 2005
Chandran Lectureship, Duke University, 2004
Member, Advisory Panel of the American College of Radiology Imaging Network, 2004
Executive Editor, Molecular Imaging, 2002
Elected Treasurer, Society for Molecular Imaging, 2001
Founding Editor, Neoplasia, 1998
Research Fellow, Association for Brain Tumor Research, 1987

Published Articles or Reviews

Recent Publications

A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy.
Ross BD, Jang Y, Welton A, Bonham CA, Palagama DSW, Heist K, Boppisetti J, Imaduwage KP, Robison T, King LR, Zhang EZ, Amirfazli C, Luker KE, Lee WY, Luker GD, Chenevert TL, Van Dort ME.
Nat Commun. 2022; 13: 4730.

Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Van Dort ME, Jang Y, Bonham CA, Heist K, Palagama DSW, McDonald L, Zhang EZ, Chenevert TL, Luker GD, Ross BD.
Eur J Med Chem. 2022; 229: 113996.

Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.
Li Y, Li B, Li W, Wang Y, Akgül S, Treisman DM, Heist KA, Pierce BR, Hoff B, Ho CY, Ferguson DO, Rehemtulla A, Zheng S, Ross BD, Li JZ, Zhu Y.
Nat Commun. 2020; 11: 3669.

Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.
Smith A, Pawar M, Van Dort ME, Galbán S, Welton AR, Thurber GM, Ross BD, Besirli CG.
J Ocul Pharmacol Ther. 2018; 34: 477–85.

Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).
Van Dort ME, Galbán S, Nino CA, Hong H, Apfelbaum AA, Luker GD, Thurber GM, Atangcho L, Besirli CG, Ross BD.
ACS Med Chem Lett. 2017; 8: 808–13.

A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.
Galbán S, Apfelbaum AA, Espinoza C, Heist K, Haley H, Bedi K, Ljungman M, Galbán CJ, Luker GD, Dort MV, Ross BD.
Mol Cancer Ther. 2017; 16: 2340–50.

Quantitative and Dynamic Imaging of ATM Kinase Activity by Bioluminescence Imaging.
Nyati S, Young G, Ross BD, Rehemtulla A.
Methods Mol Biol. 2017; 1599: 97–111.

For a list of publications from Pubmed, click HERE